ExploraMed

ExploraMed is a venture-backed medical technology incubation company. The company's medical technology incubator is used to leverage substantial financial and intellectual resources to accelerate the creation and establishment of new medical technologies, procedures, and businesses. It is dedicated to the identification, creation, and development of new medical devices which match certain key fundamental criteria and add capital, intellectual property, and expertise in the fields of clinical, engineering, legal, strategic marketing, and financing, while focusing on efficient and timely development that enable clinicians to meet the unmet health needs of patients around the world.

Joshua Makower

Founder and Executive Chairman

4 past transactions

Willow

Series A in 2015
Willow is a female technology company that develops an in-bra wearable breast pump, replacement parts, breastfeeding essentials, pumping bras, cases and bags, breastfeeding essentials, and more.

Nuelle

Series A in 2014
Nuelle is a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women. It marries its experience in healthcare solutions, consumer products, and technology with a deep understanding of women’s unfulfilled needs. From inception, Nuelle has taken a holistic view of these needs and desires. They worked closely with thought leaders and experts in women’s sexual medicine and wellness including physicians, sex therapists, physical therapists, and psychologists. Together we developed insights that allow Nuelle to translate its scientific approach to understanding.

Vibrynt

Series A in 2007
Vibrynt operates in the medical device sector and offers a system designed to assist with weight loss by limiting food consumption.

Neotract

Venture Round in 2006
NeoTract, Inc. develops surgical devices for urological and gynecological disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.